



Orlando, Florida
6-11 de noviembre de 2026

2026

CONGRESO ACR

La reumatología española en ACR Convergence 2026.
Una selección de los trabajos y las personas que contribuyen
al avance de nuestra especialidad.



Editorial

Queridos compañeros y compañeras:

Nos vamos a Orlando. Con motivo de ACR Convergence 2026, hemos preparado esta newsletter para acompañaros durante el congreso y ayudaros a encontrar los trabajos de nuestros equipos.

Hemos reunido los pósteres por temáticas y una selección de diez trabajos destacados. También felicitamos a los participantes del EULAR-ACR Research Exchange y a quienes han obtenido una beca para asistir.

Detrás de cada póster hay preguntas que nacen en la consulta, muchas horas de trabajo y un equipo. Gracias a todos los que habéis contribuido a esta edición.

Esperamos que os ayude a organizar la agenda, descubrir proyectos y poner cara a compañeros.

¡Nos vemos en Orlando!



**Sociedad Española de
Reumatología**

Y no olvidéis...

CENA INSTITUCIONAL DE LA SER

Una ocasión para reencontrarnos y compartir lo que nos está dejando el congreso.

¿PRESENTAS UN PÓSTER?

Buscamos personas que quieran grabar una breve explicación de su trabajo.

Contacta con JovReum y lo organizamos.

JovReum

El grupo de jóvenes reumatólogos de la Sociedad Española de Reumatología.

01. CONECTAR

Conocer a compañeros y compartir ideas, experiencias y oportunidades.

03. ¿TE UNES?

Si eres residente o especialista en Reumatología menor de 40 años, este es tu grupo.

Un espacio para conocernos, compartir proyectos y participar en el futuro de nuestra especialidad.

02. PARTICIPAR

Formación, investigación y proyectos que nacen de nuestras inquietudes.

04. ESCRÍBENOS

geiser@ser.es
Asunto: Solicitud JOVREUM
Incluye nombre, email y centro.




Índice

Editorial	2	Enfermedad de Sjögren	13
JovReum	3	Patología microcristalina	14
Resultados 2026 y distribución de pósteres	5	Osteoporosis y metabolismo óseo	14
Artritis reumatoide	6-7	Artrosis	14
Lupus eritematoso sistémico y cutáneo	8-9	Miscelánea	15
Síndrome antifosfolípido	9	EULAR-ACR Research Exchange	16
Vasculitis y polimialgia reumática	10-11	Becas ACR 2026	17
Síndromes autoinflamatorios	11	Recepción institucional de la SER	18
Otras enfermedades sistémicas	11	WANTED: grabaciones de pósteres	19
Espondiloartritis y artritis psoriásica	12		
Esclerosis sistémica	13		
Miopatías	13		

Pósteres

RESULTADOS 2026

Esta newsletter presenta 139 pósteres relacionados con la reumatología española en ACR Convergence 2026. La artritis reumatoide es el área más representada, seguida por el lupus, la vasculitis y la polimialgia reumática.



En las siguientes páginas se presenta esta selección de pósteres, con número, título, un autor o autora y fecha. **JovReum ha seleccionado diez trabajos destacados** de diversas áreas de la reumatología por su relevancia científica y su contribución al avance de la especialidad. **Estos se identifican con el símbolo ★.**

ARTRITIS REUMATOIDE

CÓDIGO	TÍTULO	AUTOR/A	FECHA
0084	Janus Kinase Inhibitors Rapidly Reduce T-Cell Immunosenescence and Epigenetic Age Acceleration in Rheumatoid Arthritis	Alfonso Peñarroya	08/11
0098	Multi-Omic Signatures Identify Sex-Specific Cardiovascular Risk Endotypes in Rheumatoid Arthritis	Raquel Granados	08/11
0102	Shared synovial and immune-cell serum signatures are associated with methotrexate-modulated clinical improvement in Early Rheumatoid Arthritis	Sagrario Corrales Díaz-Flores	08/11
★ 0131	Integrated Serum Proteomics and Autoantibody Analyses Reveal a Biomarker Signature Predictive of Flare During Biologic Tapering in Rheumatoid Arthritis	Lucía Lourido Salas	08/11
0448	Effect of Nintedanib Associated to Abatacept in Rheumatoid Arthritis-Associated Interstitial Lung Disease. National Multicenter Study of 526 Patients.	Pilar Ortiz	08/11
0452	Frailty and Treatment Safety in Elderly-Onset Rheumatoid Arthritis: Usefulness of the FRAIL Scale	Inés Huerta	08/11
0461	Persistence and optimization of baricitinib in rheumatoid arthritis in real-world practice: survival analysis, causes of discontinuation, and predictive factors	Daniel Campos	08/11
0462	Prescription Patterns, Safety, and Drug Survival of Targeted Therapies in Patients with Rheumatoid Arthritis-Associated Interstitial Lung Disease: Data from the BIOBADASER Registry.	Juan Camilo Sarmiento-Monroy	08/11
0465	Real-world safety of baricitinib in rheumatoid arthritis: Incidence and predictors of herpes zoster and cardiovascular events	Daniel Campos	08/11
0470	Treatment Patterns in Rheumatoid Arthritis-Associated Interstitial Lung Disease Compared with Other Autoimmune-Associated ILDs: Insights from a Real-World Cohort	Isabel Matute-Gajardo	08/11
0478	Baricitinib in rheumatoid arthritis-associated interstitial lung disease: a national multicenter study of 84 patients	Laura Muñoz	08/11
0509	Subclinical Inflammation by Power Doppler Ultrasound in Rheumatoid Arthritis in Recent Clinical Remission: Baseline Analysis of a Prospective Cohort	Esther Vicente-Rabaneda	08/11
0703	Upadacitinib in Rheumatoid Arthritis-Associated Interstitial Lung Disease: Real-World Effectiveness and Safety from a National Multicenter Cohort	Pilar Ortiz	08/11
0760	Lung ultrasound within a screening strategy for ruling out interstitial lung disease in rheumatoid arthritis	Helena Borrell	08/11
0838	Comparative Effectiveness of JAK Inhibitors Versus Abatacept in Rheumatoid Arthritis-Associated Interstitial Lung Disease: A National Multicenter Cohort of 667 Patients	Pilar Ortiz	08/11
1035	A Human Joint-on-a-Chip Platform Reveals Anti-inflammatory Effects of Cytokine-Rich Autologous Serum Derived from Patients with Rheumatoid Arthritis	Clara Eyre	09/11

ARTRITIS REUMATOIDE

CÓDIGO	TÍTULO	AUTOR/A	FECHA
1058	Peripheral Treg and CD28-Negative T-Cell Profiles in Rheumatoid Arthritis Reflect Inflammatory and Clinical Burden More Than Age at Onset	Clara Eyre	09/11
1421	Rituximab for Inflammatory Ocular Disease in Rheumatoid Arthritis: A Systematic Review of Clinical Outcomes	Juan Pablo Baldivieso	09/11
1440	Evaluation of a screening strategy for interstitial lung disease in rheumatoid arthritis	Helena Borrell	09/11
1455	Pulmonary Ultrasound Is a Useful Tool for Screening Interstitial Lung Disease Associated to Rheumatoid Arthritis	Karen Carpio	09/11
1457	Relationship Between Anti-CarP Antibodies and Estimated Cardiovascular Risk in Patients with Rheumatoid Arthritis	Pablo Martínez	09/11
1458	Rheumatoid arthritis as accelerated immune aging: telomere length, immunosenescence and interstitial lung disease in a systematic review and meta-analysis	Jorge Juan Fragío	09/11
1462	Study Of Neuropeptides In Rheumatoid Arthritis And Their Role In The Inflammatory Response	Andrés Pérez	09/11
1699	Ultrasound Evaluation of Muscle Quality in Rheumatoid Arthritis: a Reliability Study of the Spanish Ultrasound Muscle Assessment in Rheumatoid arthritis (SpUMAR) Score	Juan Molina-Collada	09/11
2025	Shared molecular signatures of treatment non-response across rheumatoid arthritis therapeutic classes reveal candidate targets for drug repurposing	Paulina Rybakowska	10/11
2022	Multi Omics Integration Reveals Treatment and Plaque Dependent Molecular Signatures in Biologic Naïve Rheumatoid Arthritis Patients Receiving csDMARDs, TNF Inhibitors or Baricitinib	Laura Muñoz-Barrera	10/11
2404	Long-Term Persistence, Effectiveness and Safety of Filgotinib in Rheumatoid Arthritis: A Multicenter Real-World Study from Three Spanish Cohorts	Cristina Oramas	10/11
2409	Risk of Cancer Associated with bDMARDs and tsDMARDs in Patients with Rheumatoid Arthritis and a History of Cancer: Insights from the ARCA Registry	Camille Bourgeois	10/11
2414	A Vision Transformer-based transfer learning approach to infer Metacarpophalangeal joint swelling from hand photographs in Rheumatoid Arthritis	Asier García-Alija	10/11
2423	Differential impact of rheumatoid factor levels on biologic persistence in rheumatoid arthritis: non-TNF inhibitors versus certolizumab pegol	Sara Salas-Santamaría	10/11
2435	Interstitial Lung Disease in Rheumatoid Arthritis: Survival Analysis Across Radiological Patterns	Martí Aguilar-Coll	10/11

LUPUS Y SAF

Lupus eritematoso sistémico y cutáneo

CÓDIGO	TÍTULO	AUTOR/A	FECHA
0253	Anifrolumab in Systemic Lupus Erythematosus with severe hematologic manifestations: an international multicentre study.	Adrián Mayo-Juanatey	08/11
0255	C4, but Not C3, Tracks Biologic Mechanism in SLE: Differential Complement Component Recovery Reveals Drug-Specific Pharmacodynamic Signatures	Pablo Martínez	08/11
0266	Effectiveness and Safety of Anifrolumab in Non-Systemic Cutaneous Lupus. Multicenter Study of 28 Patients from Clinical Practice	Ligia Gabrie Rodríguez	08/11
0277	Real-World Impact of Anifrolumab in Systemic Lupus Erythematosus: Insights from a Nationwide Spanish Multicenter Registry.	Carmen Secada-Gómez	08/11
0278	Real-world Outcomes in Systemic Lupus Erythematosus Patients Treated with Anifrolumab in Spain	Josefina Cortés-Hernández	08/11
0290	Anti-Nucleosome Antibodies are associated with Early Damage Accrual in Systemic Lupus Erythematosus: a retrospective Cohort Study.	Luis Bausá	08/11
0293	Association of Urinary Proteomic Biomarkers with Disease Activity Parameters in Patients with Systemic Lupus Erythematosus and Lupus Nephritis	Guillermo González	08/11
0297	Cervical Cytological Findings and Human Papillomavirus Infection in Systemic Lupus Erythematosus: Frequency and Impact of a Treat to Target (T2T) Strategy in a Spanish Single Center Cohort	Laura Muñoz	08/11
0305	Deep Renal Response at 24 months in Lupus Nephritis	Guillermo González	08/11
0308	Early proteinuria reduction predicts complete renal response at 12 months in first-episode lupus nephritis	Paola Vidal-Montal	08/11
0309	Early Versus Late Anifrolumab Initiation in SLE: Real-World Effectiveness and Glucocorticoid-Sparing Outcomes	Carmen Secada-Gómez	08/11
0330	Previous Biologic Exposure Does Not Impact Anifrolumab Effectiveness or Safety: Real World Data from a Nationwide Spanish SLE Cohort	Adrián Martín-Gutiérrez	08/11
0341	Urinary Biomarkers in Systemic Lupus Erythematosus: Association with Cardiovascular Risk and Potential Clinical Utility.	Marta de la Rubia-Navarro	08/11
0806	Cause-Specific Mortality in Incident Systemic Lupus Erythematosus: A Population-Based Cohort Study.	José A. Gómez-Puerta	08/11
1250	Anti-ribosomal p antibodies in systemic lupus erythematosus are not associated with neurological manifestations: a cross-sectional cohort study.	Mónica Cubells	09/11
1270	Interleukin-2 Is Associated with Cytopenias in Systemic Lupus Erythematosus	Iván Ferraz	09/11
1297	Ultrasensitive Quantification Reveals Higher Serum Interferon-α and Interferon-γ Levels Associate with Reduced Leukocyte and Lymphocyte Counts in Systemic Lupus Erythematosus	José Viotti	09/11
1982	Baseline Immunometabolic Signatures Predict Future Disease Worsening in Clinically Stable Systemic Lupus Erythematosus	Lydia Formanti-Alonso	10/11

LUPUS Y SAF

Lupus eritematoso sistémico y cutáneo

CÓDIGO	TÍTULO	AUTOR/A	FECHA
2003	Integrated Transcriptomic and Autoantibody Profiling in Systemic Lupus Erythematosus Associate with Distinct Organ-Specific Clinical Phenotypes	Ismael Sánchez Pareja	10/11
2215	Multicenter Real-World Registry of Anifrolumab (ANIFRO-REU) in Systemic Lupus Erythematosus: Effectiveness in Patients with Articular and Cutaneous Manifestations with up to 12 Months of Follow-up	Irene Carrión-Barberà	10/11
2235	Characterizing systemic lupus erythematosus associated myocarditis: from rare clinical disease to subclinical involvement	Francisco Javier Narváez	10/11
2271	Reappraising Systemic Lupus Erythematosus-Associated Interstitial Lung Disease: Not as benign as expected	Francisco Javier Narváez	10/11
2272	Relationship Between Disease Activity, Organ Damage, and Functional Status in Systemic Lupus Erythematosus: Insights for Treat to Target Implementation in a Spanish Single Center Cohort	Rafael Gálvez	10/11

Síndrome antifosfolípido

CÓDIGO	TÍTULO	AUTOR/A	FECHA
0865	The endothelial activation and stress index (EASIX) predicts Clinical Progression to Antiphospholipid Syndrome in Antiphospholipid Antibody Carriers	Rafael Gálvez	08/11
1741	DIAPS evolution among antiphospholipid antibody carriers: impact of serological profile, associated diseases and primary thromboprophylaxis.	Rafael Gálvez	09/11
1813	Clinical Phenotype of Thrombotic Antiphospholipid Patients Not Fulfilling the 2023 ACR/EULAR Criteria	Rafael Gálvez	09/11
★ 1815	Impact of the 2023 ACR/EULAR Classification Criteria on Long-Term Outcomes in a Large Thrombotic Antiphospholipid Cohort	Rafael Gálvez	09/11
2801	Perioperative Complement Inhibition with Eculizumab in High-Risk Antiphospholipid Syndrome: A Case Series	Elena de la Mata	10/11

VASCULITIS Y PMR

Vasculitis y PMR

CÓDIGO	TÍTULO	AUTOR/A	FECHA
0004	Baseline and early longitudinal serum biomarkers in Polymyalgia Rheumatica: kinetics and associations with clinical course	Pablo Muñoz-Martínez	08/11
0169	Effectiveness and safety of biosimilar tocilizumab in patients with giant cell arteritis who previously were receiving the original tocilizumab. Real-world clinical practice	Carmen Secada-Gómez	08/11
0170	Effectiveness and Safety of Janus Kinase Inhibitors in Refractory Takayasu Arteritis: A Multicenter Caucasian Cohort and Systematic Literature Review	Ligia Gabrie Rodríguez	08/11
0175	Is Image Remission By 18F-FDG PET/CT Possible In Patients With Giant Cell Arteritis: Importance of Delayed Imaging.	Felipe Moreno	08/11
0176	JAK Inhibitors in Giant Cell Arteritis: A Systematic Review and Meta-Analysis Supporting Upadacitinib Efficacy and Glucocorticoid Reduction	Mireia Sanmartín	08/11
0184	Real World Effectiveness and Safety of Upadacitinib in Giant Cell Arteritis	Fabrizio Benavides	08/11
0187	Sarilumab in Refractory and/or Glucocorticoid-Dependent Polymyalgia Rheumatica Beyond the SAPHYR Trial: Real-World Outcomes from a Multicenter Spanish Cohort	Felipe Moreno	08/11
0190	Ultrasound Supports a Shared Disease Spectrum Between Giant Cell Arteritis and Polymyalgia Rheumatica: A Cross-Sectional Study	Pablo Martínez	08/11
0204	Predictors of Remission and Comparative Safety in ANCA Associated Vasculitis: Real World Analysis of Cyclophosphamide vs Rituximab	Fabrizio Benavides	08/11
0778	Women Experience Greater Glucocorticoid Toxicity Despite Similar Exposure in Giant Cell Arteritis	Pilar Ortiz	08/11
1123	Clinical Response and Glucocorticoid Sparing With JAK Inhibitors in Takayasu Arteritis: A Disease-Specific Systematic Review and Meta-analysis.	Roxana González	09/11
1128	Early Versus Delayed Tocilizumab in Giant Cell Arteritis: Exploring the Window of Opportunity.	Adrián Martín-Gutiérrez	09/11
1153	Data-Driven Phenotyping Identifies Six Distinct Clinical and Prognostic Patterns in ANCA-Associated Vasculitis	Ligia Gabrie Rodríguez	09/11
1168	Remission and Glucocorticoid Sparing With Mepolizumab and Benralizumab in Eosinophilic Granulomatosis With Polyangiitis: A Systematic Review of Randomized and Real-World Evidence.	Roxana González	09/11
1606	Aortic Aneurysms In Patients With And Without Giant Cell Arteritis. A Clinical And Histopathological Study	Adrián Martín-Gutiérrez	09/11
★ 1666	Incidence And Factors Associated With Serious Infections In Giant Cell Arteritis: Data From The ARTESER Registry.	Adrián Martín-Gutiérrez	09/11
1752	Incidence And Predictors Of Major Adverse Cardiovascular Events In Giant Cell Arteritis: Data From The ARTESER Multicentre Registry.	Adrián Martín-Gutiérrez	09/11

VASCULITIS Y PMR

Vasculitis y PMR

CÓDIGO	TÍTULO	AUTOR/A	FECHA
1945	Single-cell profiling of peripheral B cells reveals disease-associated naïve B-cell states and altered inflammatory programs in IgA vasculitis	Joao Carlos Batista-Liz	10/11
1779	Correlation Between Cumulative Glucocorticoid Dose and Glucocorticoid Toxicity Index in Giant Cell Arteritis: A Real-World Longitudinal Study.	Pilar Ortiz	09/11
2098	Can cluster analysis redefine phenotypes in giant cell arteritis? Data from the ARTESER registry.	Carmen Secada-Gómez	10/11
2105	Does early DMARD initiation modify relapse risk in giant cell arteritis? A real-world cohort study.	Carlota Ureta	10/11
2684	18F-FDG-PET/MR imaging in treated large-vessel vasculitis: distinguishing persistent vascular uptake from active mural inflammation	Francisco Javier Narváez	10/11
2761	Precision Phenotyping of Aortitis: A Cluster Based Study from a Referral Vasculitis Clinic	Carmen Secada-Gómez	10/11

Síndromes autoinflamatorios

CÓDIGO	TÍTULO	AUTOR/A	FECHA
0125	Subclinical inflammation in patients with Familial Mediterranean Fever with well-controlled disease.	Alba María Torrat	08/11
0679	Epidemiology of adult-onset still's disease in northern spain: a 24-year population-based study.	Laura Muñoz	08/11
0702	Ultrasound-assessed enthesitis and disease severity in SAPHO syndrome	Adrián Sánchez	08/11
2624	Factors associated with initiation of conventional and biological/targeted synthetic DMARDs in SAPHO síndrome. Results from SAPHO-SPAIN registry.	Mar Rodríguez	10/11

Otras enfermedades sistémicas

CÓDIGO	TÍTULO	AUTOR/A	FECHA
0675	Clinical Characteristics, Outcomes, and Predictors of Progressive Pulmonary Fibrosis in Autoimmune-Associated Interstitial Lung Disease	Montserrat Bordoy-Pastor	08/11
2619	Eosinophilic Fasciitis: Experience at a tertiary care center and favorable response to tocilizumab in six refractory cases.	Sonia Jiménez	10/11
2628	Idiopathic Granulomatous Mastitis: Clinical Characteristics, Management and Outcomes in Sigle-Center Cohort	Clara Churtichaga	10/11
2642	Unsuspected Extrapulmonary Involvement Detected by PET/CT in Newly Diagnosed Sarcoidosis	Judith Vidal-Ripoll	10/11

SPA Y APS

CÓDIGO	TÍTULO	AUTOR/A	FECHA
0069	Altered circulating B-cell subsets in axial spondyloarthritis and their association with anti-TNF treatment response	María-Eugenia Miranda-Carús	08/11
0351	Bimekizumab Experience in Spondyloarthritis and Psoriatic Arthritis in Routine Clinical Practice in Spain: The BIMPACT Study	Cristina Valero-Martínez	08/11
0393	Optimizing the Use of Patient-Reported Outcome Measures in Axial Spondyloarthritis: A Mixed-Methods Study from the QUESTIONAX Project	Victoria Navarro-Compán	08/11
1322	Long-term Real-World Outcomes of Double Targeted Therapy in Refractory Spondyloarthritis: A Multicenter Observational Study	Cristina Calomarde-Gómez	09/11
2330	Early axial spondyloarthritis: clinical characteristics and drug survival	Iago Alcántara	10/11
0363	Long-Term Persistence and Effectiveness of Risankizumab in Multi-Refractory Psoriatic Arthritis: A 16-Center Real-World Registry (SKYREAL)	María Vanesa Hernández	08/11
0367	New-onset Non-infectious Uveitis in Patients with Axial Spondyloarthritis Treated With Upadacitinib and Monoclonal TNF Inhibitors	Victoria Navarro-Compán	08/11
0390	Lipoprotein(a) Identifies an Atherogenic Cardiovascular Profile Independent of Disease Activity in Psoriatic Arthritis: External Validation of the CARMA Cohort	Jorge Muñoz	08/11
0693	Real-world effectiveness of Bimekizumab in refractory uveitis associated with spondyloarthritis: a multicenter study	Carmen Secada-Gómez	08/11
1330	Survival Of Biological Therapy According To Sex And HLA-B27 Positivity In Patients With Spondyloarthritis	Iván del Bosque	09/11
2287	Can a Multidisciplinary Model Improve the Management of Complex IBD-SpA Cases? Insights from Gastroenterology-Rheumatology-Pharmacy Multidisciplinary Meetings	Manuel Juárez-García	10/11
★ 2070	Fine-mapping of the HLA region identifies independent susceptibility alleles in psoriatic arthritis	Lucía Santiago-Lamelas	10/11
2333	Impact of Expert Sacroiliac MRI Reassessment in Patients Referred for Clinical-Radiological Discordance in Suspected Axial Spondyloarthritis	Sheila Martín-Lázaro	10/11
★ 2540	Impact of an Integrated Primary Care-Rheumatology Referral Pathway on Diagnostic Delay in Axial Spondyloarthritis: Results from the EspAnde Project	Ligia Gabriele Rodríguez	10/11
2786	Longitudinal Inflammatory Biomarker Outcomes and Treatment Persistence With Bimekizumab in a Real-World Cohort	Samantha Rodríguez-Muguruza	10/11

SSC, MIOPATÍAS Y SJÖGREN

Esclerosis sistémica

CÓDIGO	TÍTULO	AUTOR/A	FECHA
1196	Prevalence and Clinical Associations of Rectal Prolapse in Patients with Systemic Sclerosis	Delia Fernández-Lozano	09/11
2174	Influence of Damage Burden in Patient-Reported Health Outcomes in Early Systemic Sclerosis	Carlos de Frías-Polo	10/11
★ 2180	Persistent Systemic Inflammation Defines a Distinct High-Risk Phenotype in Systemic Sclerosis: Insights from the EUSTAR PERSISTS Study (PERsistent Systemic Inflammation in SysTemic Sclerosis)	Cristiana Sieiro	10/11

Miopatías

CÓDIGO	TÍTULO	AUTOR/A	FECHA
0664	Prevalence and risk factors of progressive pulmonary fibrosis in antisynthetase syndrome-associated interstitial lung disease according to the 2022 and 2024 criteria.	Laia de Daniel Bisbe	08/11
2584	Anti-Mi-2-positive interstitial lung disease: a distinct clinical subgroup?	Francisco Javier Narváez	10/11
2595	Myocardial Involvement In Idiopathic Inflammatory Myopathies	Natalia Molina-Esteban	10/11
2600	Refractory Disease and Therapeutic Escalation in Idiopathic Inflammatory Myopathies: Differences Across Clinical Subtypes from a 25-Year Real-World experience	Rafael Gálvez	10/11
2623	Expanding the Clinical Significance of anti-Mi2 Antibodies: Real-world data from a single center	Francisco Javier Narváez	10/11

Enfermedad de Sjögren

CÓDIGO	TÍTULO	AUTOR/A	FECHA
★ 1374	Distinct Factors Associated with Patient-Reported Symptom Burden and Systemic Disease Activity in Sjögren's Disease	Olga Rusinovich	09/11
1379	Extraglandular manifestations in primary Sjögren's syndrome	Blanca Alonso	09/11
1387	Neurological manifestations in primary Sjögren's syndrome	Blanca Alonso	09/11
2353	Associations of salivary gland ultrasonographic findings with clinical features in primary Sjögren syndrome	Sheila Melchor	10/11
2370	May ultrasonography replace labial salivary gland biopsy and salivary gland flow rate assessment ?	Sheila Melchor	10/11
2376	Sjögren's Syndrome and Cutaneous Manifestations: A High-Risk Phenotype for Systemic Involvement	Cristina Calvo	10/11
2378	Transition From Conventional to Minimally Invasive Minor Salivary Gland Biopsy in Rheumatology Practice: A Real-World Safety and Feasibility Study.	Eva Álvarez	10/11

Cristales, OP y Artrosis

Patología microcristalina

CÓDIGO	TÍTULO	AUTOR/A	FECHA
0706	“Do Women Experience the Same Clinical Symptoms of Gout?”: A Systematic Literature Review	Pablo Riesgo	08/11
★ 0715	Isolated, Metabolic, and Hypertensive Gout: A Population-Based Cluster Analysis of 94,759 Patients	César Díaz-Torné	08/11
0720	Urate burden in type 2 diabetes across the cardio-kidney-metabolic (CKM) syndrome.	José Doménech-Serrano	08/11
1654	Prevalence and Factors Associated with Crowned Dens and Crowned Dens Syndrome in Patients with Calcium Pyrophosphate Arthritis	Leire Suárez-Zorrilla	09/11

Osteoporosis y metabolismo óseo

CÓDIGO	TÍTULO	AUTOR/A	FECHA
0621	Beyond Closing the Treatment Gap: Clinical and System-Level Determinants of Osteoporosis Treatment Initiation After Fragility Fracture in an Interhospital Fracture Liaison Service	Carlos María Lizasoain	08/11
0627	Osteoporosis Matters: Impact of Anti-osteoporotic Treatment on Mortality following Osteoporotic Hip Fracture	Pedro José Manuel Hernández	08/11
2549	Abdominal Aortic Calcification Is Associated With Higher Fracture Risk Despite Preserved Lumbar Bone Density in Postmenopausal Women	Regina Faré-García	10/11
2555	Effect of Romosozumab on Bone Metabolism, Lipid Profile, and Laboratory Parameters in Real-World Clinical Practice.	Mitndbaim Aelohim Parra	10/11

Artrosis

CÓDIGO	TÍTULO	AUTOR/A	FECHA
★ 0111	Choline as a Food-Derived Metabolite Linking Synovitis to Osteoarthritis Progression	Rocío Paz-González	08/11
2699	Radiographic Severity Influences Intra-Articular Therapeutic Strategies in Osteoarthritis: A Real-World Analysis of 832 Procedures	Ligia Gabriele Rodríguez	10/11

Miscelánea

CÓDIGO	TÍTULO	AUTOR/A	FECHA
0681	Humoral responses to recombinant varicella-zoster virus vaccine in patients with chronic arthritis starting JAK inhibitor therapy.	Raquel Zas	08/11
0729	Autoimmune Manifestations After Parvovirus B19 Infection: A Clinical Observational Study.	Leire Suárez-Zorrilla	08/11
0730	Management of anti-TNF therapy in patients with leishmaniasis: is it necessary to suspend biological treatment?	José Andrés Rodríguez	08/11
0740	Hypogammaglobulinemia in Patients With Inflammatory Rheumatic Diseases Treated With IL-6 Receptor Inhibitors: A Retrospective Comparative Cohort Study.	Elisabet Perea	08/11
0789	Fourteen-Year Outcomes of an Integrated Rheumatology-Primary Care Musculoskeletal Unit: Effects on Access to Care and Referral Patterns	Ligia Gabriele Rodríguez	08/11
★ 1091	Integrated multi omics and machine learning identify diagnosis-independent endotypes and predictive clinical proteomic signatures in rheumatoid arthritis and systemic lupus erythematosus	Tomás Cerdó	09/11
1390	Predictors of Severe Infection and Exploratory Risk Stratification in Systemic Lupus Erythematosus and Primary Sjögren Syndrome	Luis Bausá	09/11
1395	Serious infections in primary Sjögren syndrome and systemic lupus erythematosus: association with treatment exposure and disease group.	Luis Bausá	09/11
2073	Inflammatory serum proteomic signature in primary Sjögren's disease identifies shared clinical endotypes in systemic lupus erythematosus: results from the BISCIONE SjD cohort	José Miguel Sequí-Sabater	10/11

EULAR-ACR Research Exchange




Asier
García-Alija

Hospital Sant Pau



José Miguel
Sequí

Hospital de la Ribera



Cristiana
Sieiro

University of Manchester

El programa EULAR-ACR Research Exchange reconoce a jóvenes investigadores destacados en reumatología y fomenta el intercambio científico entre Europa y Estados Unidos. Los seleccionados podrán colaborar con equipos internacionales, explorar nuevas líneas de investigación y establecer alianzas científicas, además de participar en ACR Convergence 2026.

60

INVESTIGACIÓN
PERSONAS
IDEAS
UN FUTURO
EN COMÚN

becados y becadas de la Sociedad Española de Reumatología

ACR Convergence 2026

Orlando · Florida · EE. UU.

Congreso: 6–11 de noviembre de 2026

Programa de becas SER: 7–11 de noviembre

CIENCIA
QUE CONECTA
PERSONAS
Y MEJORA
VIDAS

Presentar trabajos. Compartir conocimiento.
Dar visibilidad a la Reumatología española.

Gracias al apoyo de las Becas ACR 2026, 60 miembros de la SER asistirán de forma presencial a uno de los principales encuentros internacionales de la especialidad.



RECEPCIÓN INSTITUCIONAL

RECEPCIÓN
SER

Domingo 8 noviembre 2026, 19.00 h
Congreso Anual del American
College of Rheumatology (ACR)

PATROCINADOR ORO
CELLTRION


COLABORADORES:
abbvie AstraZeneca Boehringer Ingelheim Gebro Pharma Lilly ucb

PARA ASISTIR ENVÍA UN CORREO A: FORMACION@SER.ES



WANTED

¿Presentas un póster
en ACR 2026?



Tu trabajo merece salir del póster.

Queremos grabarte durante el congreso
contando qué habéis investigado
y qué habéis encontrado.

¿TE APUNTAS?

Contacta con:

José Miguel Sequí (josequisab@gmail.com)

Asier García-Alija (asiereuvi@gmail.com)